Intercept to Report Full Year 2014 Financial Results on March 2 and Present at Upcoming Conferences

NEW YORK, Feb. 23, 2015 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver diseases, today announced that it will report 2014 full year financial results before the NASDAQ Market opens on Monday, March 2, 2015. Intercept management will conduct a conference call and audio webcast on Monday, March 2, 2015 at 8:30 a.m. ET to discuss these results.

Mark Pruzanski, M.D., President and Chief Executive Officer, will also be presenting at the Cowen & Company Healthcare Conference on Tuesday, March 3, 2015 at 11:20 a.m. ET in Boston.

Dial-in and webcast information for these events will be available on the Investors page of Intercept's website at Archived webcasts will be available on Intercept's website for approximately two weeks.

Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat orphan and more prevalent liver and other diseases utilizing its expertise in bile acid chemistry. The company's lead product candidate, obeticholic acid (OCA), is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR). OCA is being developed for a variety of chronic liver diseases including primary biliary cirrhosis (PBC), nonalcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC). OCA has received breakthrough therapy designation from the FDA for the treatment of NASH with fibrosis. OCA has also received orphan drug designation in both the United States and Europe for the treatment of PBC and PSC. Intercept owns worldwide rights to OCA outside of Japan, China and Korea, where it has out-licensed the product candidate to Sumitomo Dainippon Pharma. For more information about Intercept, please visit the Company's website at:

CONTACT: For more information about Intercept, please contact Barbara Duncan or Senthil Sundaram, both of Intercept Pharmaceuticals at 1-646-747-1000. Media inquiries: Investor inquiries: investors@interceptpharma.comSource:Intercept Pharmaceuticals, Inc.